CompletedPhase 1NCT06888115

A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

Studying Primary biliary cholangitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Cascade Pharmaceuticals, Inc
Principal Investigator: Zhao wei feng, Master
The First Affiliated Hospital of Soochow University
Intervention: CS0159(drug)
Enrollment: 24 target
Eligibility: 18-75 years · All sexes
Timeline: 2025 – 2025

Study locations (3)

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06888115 on ClinicalTrials.gov

Other trials for Primary biliary cholangitis

Additional recruiting or active studies for the same condition.

See all trials for Primary biliary cholangitis →

← Back to all trials